Press release: dupixent® fda approved as first and only treatment indicated for children aged 1 year and older with eosinophilic esophagitis (eoe)

Dupixent ® fda approved as first and only treatment indicated for children aged 1 year and older with eosinophilic esophagitis (eoe) approval based on phase 3 eoe kids trial showing a greater proportion of children taking dupixent achieved histological remission compared to placebo   expanded indication marks second disease for which dupixent is approved in children this young, underscoring the commitment to bringing therapies to young patients with significant unmet needs   eoe is one of five fda-approved indications for dupixent in the u.s. for which type 2 inflammation is an underlying driver paris and tarrytown, n.y. january 25, 2024.
REGN Ratings Summary
REGN Quant Ranking